<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01251484</url>
  </required_header>
  <id_info>
    <org_study_id>BIBF1120 GBM</org_study_id>
    <nct_id>NCT01251484</nct_id>
  </id_info>
  <brief_title>BIBF 1120 in Recurrent Glioblastoma Multiforme</brief_title>
  <official_title>Phase II Study of BIBF 1120 in Recurrent Glioblastoma Multiforme</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ulrik Lassen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rigshospitalet, Denmark</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      VEGF inhibition by BEV may induce a change in tumor invasiveness and treatment failure is&#xD;
      often associated with remote metastases. BEV may stop the growth of tumor cells by blocking&#xD;
      blood flow to the tumor. Cediranib, a pan-VEGF inhibitor has shown promising results in&#xD;
      recurrent GBM.&#xD;
&#xD;
      VEGF-blocking with small molecules may overcome the mechanism of resistance, and response to&#xD;
      BIBF-1120 in such circumstances may open a new treatment option in GBM. In additional,&#xD;
      recurrent glioblastomas have an extremely poor prognosis, so innovative therapies are needed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Response evaluation every 8 weeks</time_frame>
    <description>MacDonald criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Assessed every 2 weeks</time_frame>
    <description>CTCAE version 4.0</description>
  </secondary_outcome>
  <enrollment type="Actual">25</enrollment>
  <condition>Recurrent Glioblastoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIBF1120</intervention_name>
    <description>Tablet 200 mg twice daily until progression</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Histological verification of primary GBM and failure after radiotherapy and TMZ&#xD;
&#xD;
             - Previously received radiotherapy and TMZ&#xD;
&#xD;
          -  More than 4 weeks since any of the following prior treatments&#xD;
&#xD;
               -  Chemotherapy (6 weeks for nitrosureas or mitomycin C)&#xD;
&#xD;
               -  Radiotherapy to nontarget lesions or lesions that are not to be biopsied&#xD;
&#xD;
               -  Investigational agents&#xD;
&#xD;
          -  More than 6 months since prior major surgery or open biopsy and recovered (only 6&#xD;
             weeks required if operation is for recurrent BGM)&#xD;
&#xD;
          -  ● ECOG performance status 0-1&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Fertile females must use anticonception (p- pills, IUD, depot injection of gestagen,&#xD;
             subdermal&#xD;
&#xD;
          -  implantation, hormonal vaginal ring or transdermal depot plaster, throughout the study&#xD;
             and 3&#xD;
&#xD;
          -  months after discontinuation of study drugs. Fertile men must use dobbelt barrier&#xD;
             method&#xD;
&#xD;
          -  (preservative with sperm inhibiting creme) or female partner uses the above mentioned&#xD;
&#xD;
          -  contraception.&#xD;
&#xD;
          -  Fertile males must use preservatives.&#xD;
&#xD;
        Exclusions criteria&#xD;
&#xD;
          -  Prior treatment with BIBF 1120 or any other VEGFR inhibitor, except bevacizumab in&#xD;
             Group 2&#xD;
&#xD;
          -  Chemo-, hormono-, radio-(except for brain and extremities) or immunotherapy or therapy&#xD;
             with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks&#xD;
             prior to treatment with the trial drug.&#xD;
&#xD;
          -  Persistence of clinically relevant therapy related toxicity from previous chemo and/or&#xD;
             radiotherapy&#xD;
&#xD;
          -  Treatment with other investigational drugs or treatment in another clinical trial&#xD;
             within the past 4 weeks before start of therapy or concomitantly with the trial&#xD;
&#xD;
          -  Therapeutic anticoagulation( except low-dose heparin and/or heparin flush as needed&#xD;
             for maintenance of an in-dwelling intravenous devise) or anti-platelet therapy (except&#xD;
             for low-dose therapy with acetylsalicylic acid&lt;325mg per day&#xD;
&#xD;
          -  Major injuries within the past 10 days prior to start of study treatment with&#xD;
             incomplete wound healing and/or planned surgery during the on-treatment study period&#xD;
&#xD;
          -  History of clinically significant haemorrhagic or thromboembolic event in the past 6&#xD;
             months&#xD;
&#xD;
          -  Known inherited predisposition to bleeding or thrombosis&#xD;
&#xD;
          -  Significant cardiovascular diseases ( i.e. uncontrolled hypertension, unstable angina,&#xD;
             history of infarction within the past 12 months prior to start of study treatment,&#xD;
             congestive heart failure &gt; NYHA II, serious cardiac arrhythmia, pericardial effusion)&#xD;
&#xD;
          -  Proteinuria CTCAE grade 2 or greater&#xD;
&#xD;
          -  Hepatic function: total bilirubin outside of normal limits; ALT or AST &gt; 1.5 ULN&#xD;
&#xD;
          -  Coagulation parameters: International normalised ratio ( INR) &gt; 2, prothrombin time&#xD;
&#xD;
             - (PT) and partial thromboplastin time (PTT) &gt; 50% of deviation of institutional ULN&#xD;
&#xD;
          -  Absolute neutrophil count ( ANC) &lt; 1500/ml, platelets &lt; 100000/ml, Haemoglobin &lt; 9.0&#xD;
             g/dl&#xD;
&#xD;
          -  Other malignancies within the past 5 years other then basal cell skin cancer or&#xD;
             carcinoma in situ of the cervix&#xD;
&#xD;
          -  Active serious infections in particular if requiring systemic antibiotic or&#xD;
             antimicrobial therapy&#xD;
&#xD;
          -  Active or chronic hepatitis C and/or B infection&#xD;
&#xD;
          -  Gastrointestinal disorders or abnormalities that would interfere with absorption of&#xD;
             the study drug&#xD;
&#xD;
          -  Serious illness or concomitant non-oncological disease such as neurologic,&#xD;
             psychiatric, infectious disease or active ulcers (gastro-intestinal tract, skin) or&#xD;
             laboratory abnormality that may increase the risk associated with study participation&#xD;
             or study drug administration and in the judgment of the investigator would make the&#xD;
             patient inappropriate for entry into the study.&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Psychological, familial, sociological or geographical factors potentially hampering&#xD;
             compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  active alcohol or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>December 1, 2010</study_first_submitted>
  <study_first_submitted_qc>December 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2010</study_first_posted>
  <last_update_submitted>October 3, 2012</last_update_submitted>
  <last_update_submitted_qc>October 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Rigshospitalet, Denmark</investigator_affiliation>
    <investigator_full_name>Ulrik Lassen</investigator_full_name>
    <investigator_title>Ulrik Lassen, MD, PH.D</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nintedanib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

